Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples